RemeGen valuation, funding and investors
RemeGen is a pharmaceutical products company based in Yantai, China. Founded in 2008, it has about 3 employees.
VALUATION · TODAY
$1.06B +0% after Growth
Range $63.5M – $1.62B · Grade DTODAY
+12 MO
$500M
$1.00B
$1.50B
2009
2011
2013
2015
2017
2019
2021
2023
2025
2027
Growth $100M
ValuationBefore first round12-month outlook: where it points, how wide it fansHover the past: the outlook shows what was predicted then
HEADCOUNT · TODAY3 employees
–6m growth
–1y growth
–2y growth
2
4
Data from Sep 2026
Predicted in 1 yr $1.06B +0% vs today
Predicted next raise $110M if a round comes
Winding-down probability 0%
- Last round
- Growth · $100M · Apr 2020
- Valuation at last round
- $966M · implied
- Headcount
- 3
- Grade
- D
- Founded
- 2008
RemeGen valuation today
VCMC values RemeGen at $1.1B today, with a range of $63.5M to $1.6B and a grade of D. The valuation starts from its last funding round, a growth round in Apr 2020.
Valuation by date (228 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2008 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Feb 2008 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Mar 2008 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Apr 2008 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 May 2008 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Jun 2008 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Jul 2008 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Aug 2008 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Sep 2008 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Oct 2008 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Nov 2008 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Dec 2008 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Jan 2009 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Feb 2009 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Mar 2009 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Apr 2009 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 May 2009 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Jun 2009 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Jul 2009 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Aug 2009 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Sep 2009 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Oct 2009 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Nov 2009 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Dec 2009 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Jan 2010 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Feb 2010 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Mar 2010 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Apr 2010 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 May 2010 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Jun 2010 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Jul 2010 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Aug 2010 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Sep 2010 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Oct 2010 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Nov 2010 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Dec 2010 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Jan 2011 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Feb 2011 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Mar 2011 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Apr 2011 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 May 2011 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Jun 2011 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Jul 2011 | $1.85M | $0.67M – $5.09M | $1.85M (0%) | before first round | – | unknown | D | 0% |
| 1 Aug 2011 | $1.85M | $0.67M – $5.09M | $1.86M (0%) | before first round | – | unknown | D | 0% |
| 1 Sep 2011 | $1.85M | $0.67M – $5.09M | $1.87M (+1%) | before first round | – | unknown | D | 0% |
| 1 Oct 2011 | $1.85M | $0.67M – $5.09M | $1.87M (+1%) | before first round | – | unknown | D | 0% |
| 1 Nov 2011 | $1.85M | $0.67M – $5.09M | $1.88M (+2%) | before first round | – | unknown | D | 0% |
| 1 Dec 2011 | $1.85M | $0.67M – $5.09M | $1.89M (+2%) | before first round | – | unknown | D | 0% |
| 1 Jan 2012 | $1.85M | $0.67M – $5.09M | $1.90M (+2%) | before first round | – | unknown | D | 0% |
| 1 Feb 2012 | $1.85M | $0.67M – $5.09M | $1.90M (+3%) | before first round | – | unknown | D | 0% |
| 1 Mar 2012 | $1.85M | $0.67M – $5.09M | $1.91M (+3%) | before first round | – | unknown | D | 0% |
| 1 Apr 2012 | $1.85M | $0.67M – $5.09M | $1.92M (+4%) | before first round | – | unknown | D | 0% |
| 1 May 2012 | $1.85M | $0.67M – $5.09M | $1.93M (+4%) | before first round | – | unknown | D | 0% |
| 1 Jun 2012 | $1.85M | $0.67M – $5.09M | $1.93M (+4%) | before first round | – | unknown | D | 0% |
| 1 Jul 2012 | $1.85M | $0.67M – $5.09M | $1.94M (+5%) | before first round | – | unknown | D | 0% |
| 1 Aug 2012 | $1.86M | $0.68M – $5.11M | $1.95M (+5%) | before first round | – | unknown | D | 0% |
| 1 Sep 2012 | $1.87M | $0.68M – $5.13M | $1.96M (+5%) | before first round | – | unknown | D | 0% |
| 1 Oct 2012 | $1.87M | $0.68M – $5.15M | $1.96M (+5%) | before first round | – | unknown | D | 0% |
| 1 Nov 2012 | $1.88M | $0.69M – $5.17M | $1.97M (+5%) | before first round | – | unknown | D | 0% |
| 1 Dec 2012 | $1.89M | $0.69M – $5.19M | $1.98M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jan 2013 | $1.90M | $0.69M – $5.21M | $1.99M (+5%) | before first round | – | unknown | D | 0% |
| 1 Feb 2013 | $1.90M | $0.69M – $5.23M | $2.00M (+5%) | before first round | – | unknown | D | 0% |
| 1 Mar 2013 | $1.91M | $0.70M – $5.25M | $2.00M (+5%) | before first round | – | unknown | D | 0% |
| 1 Apr 2013 | $1.92M | $0.70M – $5.27M | $2.01M (+5%) | before first round | – | unknown | D | 0% |
| 1 May 2013 | $1.93M | $0.70M – $5.29M | $2.02M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jun 2013 | $1.93M | $0.70M – $5.31M | $2.03M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jul 2013 | $1.94M | $0.71M – $5.33M | $2.03M (+5%) | before first round | – | unknown | D | 0% |
| 1 Aug 2013 | $1.95M | $0.71M – $5.35M | $2.04M (+5%) | before first round | – | unknown | D | 0% |
| 1 Sep 2013 | $1.96M | $0.71M – $5.37M | $2.05M (+5%) | before first round | – | unknown | D | 0% |
| 1 Oct 2013 | $1.96M | $0.71M – $5.39M | $2.06M (+5%) | before first round | – | unknown | D | 0% |
| 1 Nov 2013 | $1.97M | $0.72M – $5.42M | $2.07M (+5%) | before first round | – | unknown | D | 0% |
| 1 Dec 2013 | $1.98M | $0.72M – $5.44M | $2.07M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jan 2014 | $1.99M | $0.72M – $5.46M | $2.08M (+5%) | before first round | – | unknown | D | 0% |
| 1 Feb 2014 | $2.00M | $0.73M – $5.48M | $2.09M (+5%) | before first round | – | unknown | D | 0% |
| 1 Mar 2014 | $2.00M | $0.73M – $5.50M | $2.10M (+5%) | before first round | – | unknown | D | 0% |
| 1 Apr 2014 | $2.01M | $0.73M – $5.52M | $2.11M (+5%) | before first round | – | unknown | D | 0% |
| 1 May 2014 | $2.02M | $0.73M – $5.54M | $2.11M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jun 2014 | $2.03M | $0.74M – $5.57M | $2.12M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jul 2014 | $2.03M | $0.74M – $5.59M | $2.13M (+5%) | before first round | – | unknown | D | 0% |
| 1 Aug 2014 | $2.04M | $0.74M – $5.61M | $2.14M (+5%) | before first round | – | unknown | D | 0% |
| 1 Sep 2014 | $2.05M | $0.75M – $5.63M | $2.15M (+5%) | before first round | – | unknown | D | 0% |
| 1 Oct 2014 | $2.06M | $0.75M – $5.65M | $2.16M (+5%) | before first round | – | unknown | D | 0% |
| 1 Nov 2014 | $2.07M | $0.75M – $5.68M | $2.17M (+5%) | before first round | – | unknown | D | 0% |
| 1 Dec 2014 | $2.07M | $0.76M – $5.70M | $2.17M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jan 2015 | $2.08M | $0.76M – $5.72M | $2.18M (+5%) | before first round | – | unknown | D | 0% |
| 1 Feb 2015 | $2.09M | $0.76M – $5.74M | $2.19M (+5%) | before first round | – | unknown | D | 0% |
| 1 Mar 2015 | $2.10M | $0.76M – $5.76M | $2.20M (+5%) | before first round | – | unknown | D | 0% |
| 1 Apr 2015 | $2.11M | $0.77M – $5.79M | $2.21M (+5%) | before first round | – | unknown | D | 0% |
| 1 May 2015 | $2.11M | $0.77M – $5.81M | $2.22M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jun 2015 | $2.12M | $0.77M – $5.83M | $2.22M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jul 2015 | $2.13M | $0.78M – $5.85M | $2.23M (+5%) | before first round | – | unknown | D | 0% |
| 1 Aug 2015 | $2.14M | $0.78M – $5.88M | $2.29M (+7%) | before first round | – | unknown | D | 0% |
| 1 Sep 2015 | $2.15M | $0.78M – $5.90M | $2.35M (+10%) | before first round | – | unknown | D | 0% |
| 1 Oct 2015 | $2.16M | $0.79M – $5.92M | $2.42M (+12%) | before first round | – | unknown | D | 0% |
| 1 Nov 2015 | $2.17M | $0.79M – $5.95M | $2.48M (+15%) | before first round | – | unknown | D | 0% |
| 1 Dec 2015 | $2.17M | $0.79M – $5.97M | $2.55M (+17%) | before first round | – | unknown | D | 0% |
| 1 Jan 2016 | $2.18M | $0.79M – $5.99M | $2.62M (+20%) | before first round | – | unknown | D | 0% |
| 1 Feb 2016 | $2.19M | $0.80M – $6.02M | $2.69M (+23%) | before first round | – | unknown | D | 0% |
| 1 Mar 2016 | $2.20M | $0.80M – $6.04M | $2.75M (+25%) | before first round | – | unknown | D | 0% |
| 1 Apr 2016 | $2.21M | $0.80M – $6.06M | $2.83M (+28%) | before first round | – | unknown | D | 0% |
| 1 May 2016 | $2.22M | $0.81M – $6.09M | $2.90M (+31%) | before first round | – | unknown | D | 0% |
| 1 Jun 2016 | $2.23M | $0.81M – $6.11M | $2.98M (+34%) | before first round | – | unknown | D | 0% |
| 1 Jul 2016 | $2.23M | $0.81M – $6.14M | $3.06M (+37%) | before first round | – | unknown | D | 0% |
| 1 Aug 2016 | $2.29M | $0.83M – $6.30M | $3.14M (+37%) | before first round | – | unknown | D | 0% |
| 1 Sep 2016 | $2.36M | $0.86M – $6.47M | $3.23M (+37%) | before first round | – | unknown | D | 0% |
| 1 Oct 2016 | $2.42M | $0.88M – $6.64M | $3.31M (+37%) | before first round | – | unknown | D | 0% |
| 1 Nov 2016 | $2.48M | $0.90M – $6.82M | $3.40M (+37%) | before first round | – | unknown | D | 0% |
| 1 Dec 2016 | $2.55M | $0.93M – $7.00M | $3.49M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jan 2017 | $2.62M | $0.95M – $7.19M | $3.59M (+37%) | before first round | – | unknown | D | 0% |
| 1 Feb 2017 | $2.69M | $0.98M – $7.38M | $3.68M (+37%) | before first round | – | unknown | D | 0% |
| 1 Mar 2017 | $2.75M | $1.00M – $7.56M | $3.77M (+37%) | before first round | – | unknown | D | 0% |
| 1 Apr 2017 | $2.83M | $1.03M – $7.77M | $3.88M (+37%) | before first round | – | unknown | D | 0% |
| 1 May 2017 | $2.90M | $1.06M – $7.97M | $3.98M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jun 2017 | $2.98M | $1.08M – $8.19M | $4.09M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jul 2017 | $3.06M | $1.11M – $8.40M | $4.19M (+37%) | before first round | – | unknown | D | 0% |
| 1 Aug 2017 | $3.14M | $1.14M – $8.63M | $4.31M (+37%) | before first round | – | unknown | D | 0% |
| 1 Sep 2017 | $3.23M | $1.17M – $8.86M | $4.42M (+37%) | before first round | – | unknown | D | 0% |
| 1 Oct 2017 | $3.31M | $1.21M – $9.10M | $4.54M (+37%) | before first round | – | unknown | D | 0% |
| 1 Nov 2017 | $3.40M | $1.24M – $9.34M | $4.66M (+37%) | before first round | – | unknown | D | 0% |
| 1 Dec 2017 | $3.49M | $1.27M – $9.59M | $4.79M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jan 2018 | $3.59M | $1.31M – $9.85M | $4.92M (+37%) | before first round | – | unknown | D | 0% |
| 1 Feb 2018 | $3.68M | $1.34M – $10.1M | $5.05M (+37%) | before first round | – | unknown | D | 0% |
| 1 Mar 2018 | $3.77M | $1.37M – $10.4M | $5.17M (+37%) | before first round | – | unknown | D | 0% |
| 1 Apr 2018 | $3.88M | $1.41M – $10.6M | $5.31M (+37%) | before first round | – | unknown | D | 0% |
| 1 May 2018 | $3.98M | $1.45M – $10.9M | $5.45M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jun 2018 | $4.09M | $1.49M – $11.2M | $5.60M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jul 2018 | $4.19M | $1.53M – $11.5M | $5.75M (+37%) | before first round | – | unknown | D | 0% |
| 1 Aug 2018 | $4.31M | $1.57M – $11.8M | $5.81M (+35%) | before first round | – | unknown | D | 0% |
| 1 Sep 2018 | $4.42M | $1.61M – $12.2M | $5.86M (+32%) | before first round | – | unknown | D | 0% |
| 1 Oct 2018 | $4.54M | $1.65M – $12.5M | $5.91M (+30%) | before first round | – | unknown | D | 0% |
| 1 Nov 2018 | $4.66M | $1.70M – $12.8M | $5.97M (+28%) | before first round | – | unknown | D | 0% |
| 1 Dec 2018 | $4.79M | $1.74M – $13.1M | $6.02M (+26%) | before first round | – | unknown | D | 0% |
| 1 Jan 2019 | $4.92M | $1.79M – $13.5M | $6.08M (+24%) | before first round | – | unknown | D | 0% |
| 1 Feb 2019 | $5.05M | $1.84M – $13.9M | $6.13M (+21%) | before first round | – | unknown | D | 0% |
| 1 Mar 2019 | $5.17M | $1.88M – $14.2M | $6.18M (+19%) | before first round | – | unknown | D | 0% |
| 1 Apr 2019 | $5.31M | $1.93M – $14.6M | $6.24M (+17%) | before first round | – | unknown | D | 0% |
| 1 May 2019 | $5.45M | $1.99M – $15.0M | $6.29M (+15%) | before first round | – | unknown | D | 0% |
| 1 Jun 2019 | $5.60M | $2.04M – $15.4M | $6.35M (+13%) | before first round | – | unknown | D | 0% |
| 1 Jul 2019 | $5.75M | $2.09M – $15.8M | $6.41M (+11%) | before first round | – | unknown | D | 0% |
| 1 Aug 2019 | $5.81M | $2.11M – $16.0M | $6.47M (+11%) | before first round | – | unknown | D | 0% |
| 1 Sep 2019 | $5.86M | $2.13M – $16.1M | $6.53M (+11%) | before first round | – | unknown | D | 0% |
| 1 Oct 2019 | $5.91M | $2.15M – $16.2M | $6.58M (+11%) | before first round | – | unknown | D | 0% |
| 1 Nov 2019 | $5.97M | $2.17M – $16.4M | $6.65M (+11%) | before first round | – | unknown | D | 0% |
| 1 Dec 2019 | $6.02M | $2.19M – $16.5M | $6.70M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jan 2020 | $6.08M | $2.21M – $16.7M | $6.77M (+11%) | before first round | – | unknown | D | 0% |
| 1 Feb 2020 | $6.13M | $2.23M – $16.8M | $6.83M (+11%) | before first round | – | unknown | D | 0% |
| 1 Mar 2020 | $6.18M | $2.25M – $17.0M | $6.89M (+11%) | before first round | – | unknown | D | 0% |
| 1 Apr 2020 | $6.24M | $2.27M – $17.1M | $6.95M (+11%) | before first round | – | unknown | D | 0% |
| 3 Apr 2020 | $966M | $635M – $1.6B | $1.1B (+10%) | after a round | – | unknown | B | 0% |
| 1 May 2020 | $974M | $635M – $1.6B | $1.1B (+9%) | after a round | – | unknown | B | 0% |
| 1 Jun 2020 | $981M | $635M – $1.6B | $1.1B (+8%) | after a round | – | unknown | B | 0% |
| 1 Jul 2020 | $989M | $635M – $1.6B | $1.1B (+7%) | after a round | – | unknown | B | 0% |
| 1 Aug 2020 | $997M | $635M – $1.6B | $1.1B (+7%) | after a round | – | unknown | B | 0% |
| 1 Sep 2020 | $1.0B | $635M – $1.6B | $1.1B (+6%) | after a round | – | unknown | B | 0% |
| 1 Oct 2020 | $1.0B | $635M – $1.6B | $1.1B (+5%) | after a round | – | unknown | B | 0% |
| 1 Nov 2020 | $1.0B | $635M – $1.6B | $1.1B (+4%) | after a round | – | unknown | B | 0% |
| 1 Dec 2020 | $1.0B | $635M – $1.6B | $1.1B (+3%) | after a round | – | unknown | B | 0% |
| 1 Jan 2021 | $1.0B | $635M – $1.6B | $1.1B (+2%) | after a round | – | unknown | B | 0% |
| 1 Feb 2021 | $1.0B | $635M – $1.6B | $1.1B (+2%) | after a round | – | unknown | B | 0% |
| 1 Mar 2021 | $1.1B | $635M – $1.6B | $1.1B (+1%) | after a round | – | unknown | B | 0% |
| 1 Apr 2021 | $1.1B | $635M – $1.6B | $1.1B (0%) | after a round | – | unknown | B | 0% |
| 1 May 2021 | $1.1B | $606M – $1.6B | $1.1B (0%) | after a round | – | unknown | B | 0% |
| 1 Jun 2021 | $1.1B | $575M – $1.6B | $1.1B (0%) | after a round | – | unknown | B | 0% |
| 1 Jul 2021 | $1.1B | $548M – $1.6B | $1.1B (0%) | after a round | – | unknown | B | 0% |
| 1 Aug 2021 | $1.1B | $521M – $1.6B | $1.1B (0%) | after a round | – | unknown | B | 0% |
| 1 Sep 2021 | $1.1B | $495M – $1.6B | $1.1B (0%) | after a round | – | unknown | B | 0% |
| 1 Oct 2021 | $1.1B | $471M – $1.6B | $1.1B (0%) | after a round | – | unknown | C | 0% |
| 1 Nov 2021 | $1.1B | $448M – $1.6B | $1.1B (0%) | after a round | – | unknown | C | 0% |
| 1 Dec 2021 | $1.1B | $426M – $1.6B | $1.1B (0%) | after a round | – | unknown | C | 0% |
| 1 Jan 2022 | $1.1B | $405M – $1.6B | $1.1B (0%) | after a round | – | unknown | C | 0% |
| 1 Feb 2022 | $1.1B | $385M – $1.6B | $1.1B (0%) | after a round | – | unknown | C | 0% |
| 1 Mar 2022 | $1.1B | $368M – $1.6B | $1.1B (0%) | after a round | – | unknown | C | 0% |
| 1 Apr 2022 | $1.1B | $349M – $1.6B | $1.1B (0%) | after a round | – | unknown | C | 0% |
| 1 May 2022 | $1.1B | $332M – $1.6B | $1.1B (0%) | after a round | – | unknown | C | 0% |
| 1 Jun 2022 | $1.1B | $316M – $1.6B | $1.1B (0%) | after a round | – | unknown | C | 0% |
| 1 Jul 2022 | $1.1B | $301M – $1.6B | $1.1B (0%) | after a round | – | unknown | C | 0% |
| 1 Aug 2022 | $1.1B | $286M – $1.6B | $1.1B (0%) | after a round | – | unknown | C | 0% |
| 1 Sep 2022 | $1.1B | $272M – $1.6B | $1.1B (0%) | after a round | – | unknown | C | 0% |
| 1 Oct 2022 | $1.1B | $259M – $1.6B | $1.1B (0%) | after a round | – | unknown | C | 0% |
| 1 Nov 2022 | $1.1B | $246M – $1.6B | $1.1B (0%) | after a round | – | unknown | C | 0% |
| 1 Dec 2022 | $1.1B | $234M – $1.6B | $1.1B (0%) | after a round | – | unknown | C | 0% |
| 1 Jan 2023 | $1.1B | $222M – $1.6B | $1.1B (0%) | after a round | – | unknown | C | 0% |
| 1 Feb 2023 | $1.1B | $211M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Mar 2023 | $1.1B | $202M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Apr 2023 | $1.1B | $192M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 May 2023 | $1.1B | $183M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Jun 2023 | $1.1B | $173M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Jul 2023 | $1.1B | $165M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Aug 2023 | $1.1B | $157M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Sep 2023 | $1.1B | $149M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Oct 2023 | $1.1B | $142M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Nov 2023 | $1.1B | $135M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Dec 2023 | $1.1B | $128M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Jan 2024 | $1.1B | $122M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Feb 2024 | $1.1B | $116M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Mar 2024 | $1.1B | $111M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Apr 2024 | $1.1B | $105M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 May 2024 | $1.1B | $100M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Jun 2024 | $1.1B | $95.1M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Jul 2024 | $1.1B | $90.5M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Aug 2024 | $1.1B | $86.0M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Sep 2024 | $1.1B | $81.7M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Oct 2024 | $1.1B | $77.8M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Nov 2024 | $1.1B | $74.0M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Dec 2024 | $1.1B | $70.4M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Jan 2025 | $1.1B | $66.9M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Feb 2025 | $1.1B | $63.6M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Mar 2025 | $1.1B | $63.5M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Apr 2025 | $1.1B | $63.5M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 May 2025 | $1.1B | $63.5M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Jun 2025 | $1.1B | $63.5M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Jul 2025 | $1.1B | $63.5M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Aug 2025 | $1.1B | $63.5M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Sep 2025 | $1.1B | $63.5M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Oct 2025 | $1.1B | $63.5M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Nov 2025 | $1.1B | $63.5M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Dec 2025 | $1.1B | $63.5M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Jan 2026 | $1.1B | $63.5M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Feb 2026 | $1.1B | $63.5M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Mar 2026 | $1.1B | $63.5M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Apr 2026 | $1.1B | $63.5M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 May 2026 | $1.1B | $63.5M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Jun 2026 | $1.1B | $63.5M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Jul 2026 | $1.1B | $63.5M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Aug 2026 | $1.1B | $63.5M – $1.6B | $1.1B (0%) | after a round | – | unknown | D | 0% |
| 1 Sep 2026 | $1.1B | $63.5M – $1.6B | $1.1B (0%) | after a round | 3 | unknown | D | 0% |
| 1 Oct 2026 | $1.1B | $63.5M – $1.6B | $1.1B (0%) | after a round | 3 | unknown | D | 0% |
| 24 Oct 2026 | $1.1B | $63.5M – $1.6B | $1.1B (0%) | after a round | 3 | unknown | D | 0% |
Key facts about RemeGen
- Founded
- 2008
- Headquarters
- Yantai, China
- Employees
- about 3
- Total raised
- $750M
- Funding rounds
- 2
- Last round
- Other Jan 2026
RemeGen funding history
RemeGen has 2 funding rounds on record, from Apr 2020 to Jan 2026, $750M in total. None disclosed a valuation.
$650M
Growth Equity 2 Apr 2020
Led by Lilly Asia Ventures, Lake Bleu Capital; with Vivo Capital, Janchor Partners, OrbiMed, Hudson Bay Capital, Loyal Valley Capital, China Reform Conson Soochow Overseas Fund.
Sources: prnewswire.com, lupusnewstoday.com
$100M
RemeGen investors
9 investors have backed RemeGen; Lake Bleu Capital and Lilly Asia Ventures led at least one round.
- Lake Bleu Capital lead
- Lilly Asia Ventures lead
- AbbVie
- China Reform Conson Soochow Overseas Fund
- Loyal Valley Capital
What RemeGen does
RemeGen is classified under pharmaceutical products. No offerings or markets are recorded yet.
RemeGen Co., Ltd. is a Chinese biopharmaceutical company engaged in the discovery, development, production, and commercialization of biological drugs for major diseases such as autoimmunity, oncology, and ophthalmology. The company operates in China and the United States, with a focus on oncology, ophthalmology, and autoimmune diseases, and serves both domestic and international markets. RemeGen is publicly listed on the STAR Market in China and the Hong Kong Stock Exchange.
Description from Veridion's company data.
Questions about RemeGen
What is RemeGen worth?
Valuation $1.1B (range $63.5M to $1.6B), as of 24 Oct 2026.
Has RemeGen raised money?
RemeGen has 2 funding rounds on record, from Apr 2020 to Jan 2026, $750M in total. None disclosed a valuation.
Who has invested in RemeGen?
Lake Bleu Capital, Lilly Asia Ventures, AbbVie, China Reform Conson Soochow Overseas Fund, Hudson Bay Capital and Janchor Partners, and 3 more. Lead investors include Lake Bleu Capital and Lilly Asia Ventures.
How many people work at RemeGen?
About 3.
When was RemeGen founded, and where is it based?
RemeGen was founded in 2008 and is based in Yantai, China. It has about 3 employees.